Le Lézard
Classified in: Health
Subjects: SVY, CPN, CFG

Canadians will make health care a ballot issue, new CMA survey


OTTAWA, ON, Sept. 13, 2021 /CNW/ - As we enter the last week of this federal election, a new survey conducted on behalf of the Canadian Medical Association (CMA) confirms that a bold commitment to health care will win voters' support.

Once considered a source of national pride, Canada's health care system is the number one area in Canadians' minds requiring federal investment (24%), surpassing the economy (22%) and affordable housing (21%). Climate change and management of the pandemic follow closely, making it clear that voters value good health, employment and housing, while recognizing that climate change and the pandemic have been, and will continue to be, disruptors that must be managed and mitigated.

"Voters are sending a very strong message to political parties and candidates ? they expect federal commitments to fix our health care system," says Dr. Katharine Smart, CMA president. "It's time to step up and take a leadership position. Canadians are ready to support you."

More than 90% of Canadians agree that federal investments in health care are needed to improve the systems, along with additional support and investments for health workers, better collaboration between provinces and the federal government.

Other key findings:

Methodology: The survey was conducted by Abacus Data with 2,000 Canadian adults eligible to vote from September 3 to 6, 2021. A random sample of panelists was invited to complete the survey from a set of partner panels based on the Lucid exchange platform. These partners are typically double opt-in survey panels, blended to manage out potential skews in the data from a single source. 3,137 panelists who were invited to complete the survey entered, but we are unable to determine how many were initially invited. Of the 3,137 who started the survey, 2,000 (63.7%) completed it, 453 (14.4%) qualified but didn't complete the survey and 684 (21.8%) were disqualified. The margin of error for a comparable probability-based random sample of the same size is +/-2.17, 19 times out of 20. The data were weighted according to census data to ensure that the sample matched Canada's population according to age, gender, educational attainment, and region. Totals may not add up to 100 due to rounding.

About the CMA
The Canadian Medical Association is the national voice of the medical profession. Our focus is on creating strong and accessible health systems, fostering well-being and diversity in medical culture, and ensuring every person in Canada has equal opportunity to be healthy. In partnership with physicians, medical learners, patients and others, we advance these goals through advocacy, knowledge sharing and granting.

Authorized by the Canadian Medical Association, cma.ca, 1-888-855-2555.

SOURCE Canadian Medical Association


These press releases may also interest you

at 06:00
BioInvent International (STO:BINV)Preliminary data presented at ESMO 2024 demonstrate BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatmentIn a patient with a heavily pretreated leiomyosarcoma, BT-001 was able to...

at 05:00
Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials;...

at 04:20
Pfizer Inc. today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for patients with BRAF V600E-mutant...

at 04:06
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announced the latest clinical data on...

at 03:20
Merck , known as MSD outside of the United States and Canada, today announced overall survival (OS) results from the final analysis of the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with...

at 03:10
Nuvation Bio Inc. , a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies evaluating taletrectinib, an...



News published on and distributed by: